ライフサイエンスコーパス: monoamine oxidase

1 of the aromatic amino acid decarboxylase and monoamine oxidase.

2 yr430 is conserved in the homologous protein monoamine oxidase.

3 a semicarbazide-sensitive copper-containing monoamine oxidase.

4 pamine to DOPAC by the mitochondrial enzyme, monoamine oxidase.

5 ut influences of active efflux mechanisms or monoamine oxidases.

6 and tested for inhibitory activities against monoamine oxidases.

7 terases, N-methyl-D-aspartate receptors, and monoamine oxidases.

8 Human monoamine oxidase A (hMAOA) is considered to be unique a

9 near the covalent 8alpha-S-cysteinyl FAD in monoamine oxidase A (MAO A) and to test the suggestion t

10 Monoamine oxidase A (MAO A) degrades serotonin, norepine

11 The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mut

12 ly shown that the serotonin-degrading enzyme monoamine oxidase A (MAO A) is an important source of hy

13 Smokers have reduced levels of brain monoamine oxidase A (MAO A) leading to speculation that

14 A spontaneous monoamine oxidase A (MAO A) mutation (A863T) in exon 8 i

15 Monoamine oxidase A (MAO A) plays a central role in the

16 The interaction of recombinant human liver monoamine oxidase A (MAO A) with a series of phenethylam

17 The genetic deletion of monoamine oxidase A (MAO A), an enzyme that breaks down

18 Monoamine oxidase A (MAO A), encoded by the X chromosome

19 Converging evidence shows that monoamine oxidase A (MAO A), the key enzyme catalyzing s

20 However, it has been reported that monoamine oxidase A (MAO A, a major neurotransmitter-deg

21 by increased blood glucocorticoids and brain monoamine oxidase A (MAO A, which degrades monoamine neu

22 Monoamine oxidase A (MAO(A)) knockout mice have highly e

23 The use of selective inhibitors of monoamine oxidase A (MAO-A) and B (MAO-B) holds a therap

24 compared to linezolid but suffer from potent monoamine oxidase A (MAO-A) inhibition and low solubilit

25 Monoamine oxidase A (MAO-A) is a key regulator of seroto

26 Monoamine oxidase A (MAO-A) is an important brain enzyme

27 Monoamine oxidase A (MAO-A) is an important enzyme on th

28 o counter the effects of the 40% increase in monoamine oxidase A (MAO-A) levels that occurs during PP

29 One such biological abnormality is elevated monoamine oxidase A (MAO-A) levels, which occurs in the

30 ylglycolaldehyde (DOPEGAL) is the neurotoxic monoamine oxidase A (MAO-A) metabolite of norepinephrine

31 ating transcription of the gene encoding the monoamine oxidase A (MAO-A) to reduce serotonin levels i

32 We found that monoamine oxidase A (MAO-A) was the most significantly u

33 zolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired

34 Monoamine oxidase A (MAOA) activity was associated with

35 region contains, among others, the genes for monoamine oxidase A (MAOA) and B (MAOB), which are invol

36 We examined the impact of constitutive monoamine oxidase A (MAOA) deficiency in mice on nicotin

37 Mice lacking monoamine oxidase A (MAOA) display high levels of brain

38 A functional promoter polymorphism in the monoamine oxidase A (MAOA) gene has been implicated as a

39 g RNA (lncRNA), acting as a regulator of the monoamine oxidase A (MAOA) gene in the brain, and named

40 examining allelic variation in the X-linked monoamine oxidase A (MAOA) gene, previously associated w

41 esonance imaging and genetic analysis of the monoamine oxidase A (MAOA) gene, we investigated how str

42 olymorphisms in dopamine receptor (DRD4) and monoamine oxidase A (MAOA) genes showed significant asso

43 (5HT) and the monoamine-metabolizing enzyme monoamine oxidase A (MAOA) have been repeatedly implicat

44 y, we identify for the first time a role for monoamine oxidase A (MAOA) in NPC.

45 We report that monoamine oxidase A (MAOA) is a clinically and functiona

46 Monoamine oxidase A (MAOA) is a mitochondrial enzyme tha

47 The rs1137070 polymorphism of monoamine oxidase A (MAOA) is associated with alcoholism

48 ohorts of Finnish prisoners, revealed that a monoamine oxidase A (MAOA) low-activity genotype (contri

49 Pharmacologic blockade of monoamine oxidase A (MAOA) or serotonin transporter (5-H

50 g growth differentiation factor-3 (GDF3) and monoamine oxidase A (MAOA) that is known to degrade nora

51 ing the neurotransmitter-metabolizing enzyme monoamine oxidase A (MAOA) was found to moderate the eff

52 6 member 2 (SLC6A2), an NE transporter, and monoamine oxidase A (MAOA), a degradation enzyme.

53 Monoamine oxidase A (MAOA), a mitochondria-bound enzyme,

54 Here, we show that upregulation of monoamine oxidase A (MAOA), a mitochondrial enzyme that

55 cancer (PCa) exhibit increased expression of monoamine oxidase A (MAOA), a mitochondrial enzyme that

56 polymorphisms affecting transcription level: monoamine oxidase A (MAOA), neuropeptide Y (NPY), endoth

57 Polymorphisms in the monoamine oxidase A (MAOA-LPR) and serotonin receptor 2A

58 rine secretion; P < 0.01), with no effect on monoamine oxidase A (serotonin catabolism), serotonin re

59 ents and four Sp1-binding sites in the human monoamine oxidase A 2-kb promoter.

60 Low monoamine oxidase A activity increased risk for conduct

61 NIRKO mice also exhibit increased levels of monoamine oxidase A and B (MAO A and B) leading to incre

62 In a screening for potential monoamine oxidase A and B inhibition ciproxifan showed e

63 ted high selectivity (>160x) against related monoamine oxidase A and B.

64 The degree of inhibition of monoamine oxidase A by R1 correlated with the level of R

65 ors, the sequences of three Sp1 sites in the monoamine oxidase A core promoter were used in the yeast

66 ryptophan hydroxylase 1 and a suppression of monoamine oxidase A expression (enzymes responsible for

67 gnificant association between high levels of monoamine oxidase A expression and poorly differentiated

68 e shown that the Sp1 family is important for monoamine oxidase A expression.

69 Monoamine oxidase A gene (MAOA) has earned the nickname

70 his study shows that glucocorticoid enhances monoamine oxidase A gene expression by 1) regulation of

71 Studies on the regulation of monoamine oxidase A gene expression have shown that the

72 s that R1 is a novel repressor that inhibits monoamine oxidase A gene expression.

73 re was a main effect of adversity but not of monoamine oxidase A on risk for conduct disorder.

74 tistically significant effects on binding to monoamine oxidase A or to the norepinephrine transporter

75 R1 was also found to repress monoamine oxidase A promoter activity within a natural c

76 toma cell line, SK-N-BE (2)-C, inhibited the monoamine oxidase A promoter and enzymatic activity.

77 R1 also bound directly to the natural monoamine oxidase A promoter in vivo as shown by chromat

78 A deficiency in monoamine oxidase A results in aggressive behavior in bo

79 d binding to the norepinephrine transporter, monoamine oxidase A, and alpha2-adrenoceptors were measu

80 ith clorgyline, an irreversible inhibitor of monoamine oxidase A, restored hippocampal noradrenaline

81 affinity to recombinant rat cerebral cortex monoamine oxidases A (MAO A) and B (MAO B) determined.

82 dent amine oxidizing enzymes including human monoamine oxidases A and B (MAO A and MAO B) show aromat

83 The monoamine oxidases A and B (MAO-A and -B) genes, which a

84 Monoamine oxidases A and B (MAO-A and MAO-B) are enzymes

85 rs with notable selectivity toward SSAO over monoamine oxidases A and B (MAO-A and MAO-B).

86 cture (which also has inhibitory activity at monoamine oxidases A and B and at the serotonin and nore

87 ty towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 recep

88 ompanied by an increase in the expression of monoamine oxidase-A (MAO-A) and MAO-B in the lateral OFC

89 Monoamine oxidase-A (MAO-A) is a treatment target in neu

90 Here we report that high expression of monoamine oxidase-A (MAO-A) is associated with positive

91 Monoamine oxidase-A (MAO-A), a key brain enzyme which me

92 cluding catechol-O-methyltransferase (COMT), monoamine oxidase-A (MAO-A), vesicular monoamine transpo

93 study examined how the mitochondrial enzyme monoamine oxidase-A (MAO-A), which produces hydrogen per

94 eas was similarly modulated by inhibition of monoamine oxidase-A and was reduced in animals with indu

95 tor), SERT RNA-interference, and iproniazid (monoamine oxidase-A inhibitor), blocked 5-HT-induced S10

96 the current study, we used a genetic model (monoamine oxidase-A knockout mouse) in which brain 5-HT

97 3,4-Dihydroxyphenylglycolaldehyde is the monoamine oxidase-A metabolite of two catecholamine neur

98 R antagonist or after incubation with MAO-A (monoamine oxidase-A).

99 luded those involved in cellular metabolism: monoamine oxidase-A, mitochondrial-A synthase complex, a

100 -serotonin and increased after inhibition of monoamine oxidase-A, the main enzyme responsible for ser

101 Recent observations of lower monoamine oxidase activity (which may play a role in cen

102 Ebselen had no effect on the monoamine oxidase activity and did not protect against M

103 dopamine transporter expression, and inhibit monoamine oxidase activity while increasing tyrosine hyd

104 K1/2 nuclear translocation depended on SERT, monoamine oxidase activity, and reactive oxygen species.

105 form (sVAP-1) accounts for most circulating monoamine oxidase activity, has insulin-like effects, an

106 o competitive MPP(+)-dependent inhibition of monoamine oxidase activity.

107 through stepwise transformation catalyzed by monoamine oxidase, aldehyde dehydrogenase and aldehyde r

108 eneration: (a) MPTP oxidation to MPP(+) by a monoamine oxidase and (b) NADH dehydrogenase inhibition

109 In addition, they showed lower activities of monoamine oxidase and dopamine beta hydroxylase in the h

110 en), and neurotransmitter enzyme inhibition (monoamine oxidase and glutamic acid decarboxylase).

111 flavoenzymes that oxidize amines, including monoamine oxidase and trimethylamine dehydrogenase.

112 enine dinucleotide (FAD) dependent family of monoamine oxidases and is vital in regulation of mammali

113 urons greatly increases the transcription of monoamine oxidases and oxidative stress, significantly r

114 cascade consisting of the ATHase, the GDH, a monoamine oxidase, and a catalase leads to the productio

115 d by the transaminase is not affected by the monoamine oxidase, and highlights the potential of this

116 As the H3R and monoamine oxidases are all capable of affecting neurotra

117 ine oxidase, copper containing 3), a surface monoamine oxidase, as a new marker of myofibroblasts by

118 The monotopic membrane protein monoamine oxidase B (MAO B) is an important drug target

119 al reversible inhibitors selective for human monoamine oxidase B (MAO B) that do not inhibit MAO A ha

120 (AD), i.e., acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), a series of multitarget lig

121 A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1)

122 mine and compare how two monotopic proteins, monoamine oxidase B (MAO-B) and cyclooxygenase-2 (COX-2)

123 Age-related increases in brain monoamine oxidase B (MAO-B) and its ability to produce r

124 l) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10

125 enosine receptors (A2AARs) and inhibition of monoamine oxidase B (MAO-B) in the brain are considered

126 llular model of Parkinson's disease in which monoamine oxidase B (MAO-B) is overexpressed and which e

127 evious finding that smokers have lower brain monoamine oxidase B (MAO-B) levels than comparison nonsm

128 Illudinine was found to inhibit monoamine oxidase B (MAO-B) with an IC(50) of 18 +/- 7.1

129 or (NMDAR), acetylcholinesterase (AChE), and monoamine oxidase B (MAO-B).

130 e, competitive, and reversible inhibitors of monoamine oxidase B (MAO-B).

131 was found to suppress the gene expression of monoamine oxidase B (MAOB) in the brain of wild-type but

132 brane domains from the mitochondrial protein monoamine oxidase B (MaoB) or the endoplasmic reticulum

133 tural comparisons with human metabolites and monoamine oxidase B (MAOB) was identified as the putativ

134 g agent, flecainide, which has no recognized monoamine oxidase B activity, and which has previously b

135 example of a biorelevant synthetic model for monoamine oxidase B activity.

136 amine N-methyl transferase) and disposition (monoamine oxidase B and catechol-O-methyl transferase) o

137 We performed a genomewide scan of monoamine oxidase B for the Collaborative Study on the G

138 trate for the flavin-dependent mitochondrial monoamine oxidase B from bovine liver.

139 a targeting enzyme to disrupt the endogenous monoamine oxidase B gene in human cells.

140 onoamine oxidases with slight preference for monoamine oxidase B in both species.

141 hydrogen peroxide (H(2)O(2)) originated from monoamine oxidase B in severe reactive astrocytes causes

142 SKF-38393 had no effects either on total or monoamine oxidase B in the striatum.

143 We report the effects of the addition of a monoamine oxidase B inhibitor, rasagiline, to antidepres

144 est placebo-controlled clinical trial of the monoamine oxidase B inhibitor, rasagiline, we examined h

145 2D6 inhibitor, quinidine, and also partly by monoamine oxidase B inhibitors deprenyl and pargyline.

146 Monoamine oxidase B inhibitors result in a mild improvem

147 his, a number of highly potent and selective monoamine oxidase B inhibitors were identified.

148 dowed with potent, selective, and reversible monoamine oxidase B inhibitory activity is a clinically

149 Also, we demonstrate that monoamine oxidase B is an ERRalpha target gene whose exp

150 -deuterium-L-deprenyl ((11)C-DED) to measure monoamine oxidase B located in astrocytes.

151 rkinson's disease based on its inhibition of monoamine oxidase B, but the drug is also a potent state

152 Monoamine oxidase B, present in the mitochondrial outer

153 nction and these include redox-related genes monoamine oxidase B, ryanodine receptor 2, and glutathio

154 rmed with 1-PCPA and mammalian mitochondrial monoamine oxidase B.

155 Monoamine oxidase-B (MAO-B) is a key enzyme in the catab

156 MPTP is converted by monoamine oxidase-B (MAO-B) to its neurotoxic metabolite

157 oduce the inhibitory gliotransmitter GABA by monoamine oxidase-B (Maob) and abnormally release GABA t

158 Monoamine oxidase-B inhibitors and dopamine agonists can

159 Measuring monoamine oxidase-B with neuroimaging and glial fibrilla

160 Accordingly, monoamine oxidase blockers pargyline and l-deprenyl had

161 hat renalase is the third monoamine oxidase (monoamine oxidase C) that oxidizes circulating catechola

162 r has been reported to bind to neuromelanin, monoamine oxidase, calcifications, iron, leptomeningeal

163 Monoamine oxidase catalyzes the oxidative deamination of

164 tabolism of dopamine involves three enzymes: monoamine oxidase, catechol O-methyltransferase, and sul

165 Monoamine oxidase converts dopamine to 3,4-dihydroxyphen

166 nhibition of either serotonin reuptake or of monoamine oxidase, dopamine neurons accumulate serotonin

167 mine (2, MBA236) as a new cholinesterase and monoamine oxidase dual inhibitor.

168 that it has the same fold as members of the monoamine oxidase family of flavoproteins, with the grea

169 Structurally, PAO is a member of the monoamine oxidase family of flavoproteins.

170 e enzyme are conserved in all members of the monoamine oxidase family, Lys365 and Trp466.

171 ved active site residue found throughout the monoamine oxidase family.

172 MAOB, a crucial monoamine oxidase for dopamine metabolism, triggers oxid

173 Monoamine oxidase from Aspergillus niger (MAO-N) is a fl

174 ndividuals or for those undergoing classical monoamine oxidase inhibiting (MAOI) drug therapy.

175 Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent

176 of smoking behavior and the contribution of monoamine oxidase inhibition to compulsive nicotine-seek

177 tudy the effects of fluorine substitution on monoamine oxidase inhibition.

178 ibitor (SSRI) fluoxetine (10 mg/kg), and the monoamine oxidase inhibitor (MAOI) phenelzine (10 mg/kg)

179 Hamsters were treated chronically with the monoamine oxidase inhibitor (MAOI), clorgyline, and then

180 uoxetine) or norepinephrine (desipramine), a monoamine oxidase inhibitor (tranylcypromine), and elect

181 ective reuptake inhibitor (fluoxetine), or a monoamine oxidase inhibitor (tranylcypromine).

182 iggers lethal phenethylamine poisoning after monoamine oxidase inhibitor administration.

183 side effects commonly seen with traditional monoamine oxidase inhibitor antidepressants were not obs

184 dose response experiments with tricyclic or monoamine oxidase inhibitor antidepressants.

185 While tricyclic and monoamine oxidase inhibitor medications were associated

186 e inhibitors desipramine and reboxetine, the monoamine oxidase inhibitor pargyline, and the atypical

187 Our lab has found opposing effects of the monoamine oxidase inhibitor phenelzine and the tricyclic

188 reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor phenelzine.

189 n has also been introduced in a study of the monoamine oxidase inhibitor rasagiline, demonstrating a

190 selective serotonin reuptake inhibitor or a monoamine oxidase inhibitor rather than a tricyclic anti

191 As part of the clinical trials of the monoamine oxidase inhibitor selegiline for treating coca

192 n by RNAi in human erythroid cells or by the monoamine oxidase inhibitor tranylcypromine in human ery

193 ibitor) and tranylcypromine (10 mg/kg, i.p., monoamine oxidase inhibitor) with each drug being inject

194 st and present clinical trials of tricyclic, monoamine oxidase inhibitor, and selective serotonin reu

195 However, neither pargyline, a specific monoamine oxidase inhibitor, nor semicarbazide, a specif

196 Combined with pargyline, a monoamine oxidase inhibitor, reserpine increased catecho

197 covery of a new class of compounds acting as monoamine oxidase inhibitors (MAO-Is) and bearing a 6'-s

198 Because monoamine oxidase inhibitors (MAOI) are often more effec

199 Monoamine oxidase inhibitors (MAOIs) exert therapeutic a

200 We previously assessed monoamine oxidase inhibitors (MAOIs) for their ability t

201 n of LSD1 or inhibition of its activity with monoamine oxidase inhibitors (MAOIs) results in the accu

202 been treated with tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), fluoxetine, or pla

203 ects on outcomes compared with waitlist were monoamine oxidase inhibitors (SMD -1.01, 95% credible in

204 ts [TCA], atypical antidepressants [AA], and monoamine oxidase inhibitors [MAOI]), age, sex, smoking,

205 Although monoamine oxidase inhibitors are effective in treating a

206 f smoking behavior in humans and presence of monoamine oxidase inhibitors in tobacco smoke, we hypoth

207 idepressants (eg, tricyclic antidepressants, monoamine oxidase inhibitors) were excluded.

208 reated with beta-blockers, ACE inhibitors or monoamine oxidase inhibitors, in children under 5 years

209 studies of the neuroprotective properties of monoamine oxidase inhibitors, we found that phenelzine p

210 and several related synthetic analogues are monoamine oxidase inhibitors, which is the first reporte

211 es and aromatic amino acid decarboxylase and monoamine oxidase inhibitors.

212 at such patients responded preferentially to monoamine oxidase inhibitors.

213 In prior studies, it has been shown that monoamine oxidase inhibitory scaffolds such as propargyl

214 etic modeling suggests a lower potential for monoamine oxidase interaction, and animal and human subj

215 Monoamine oxidase is an outer mitochondrial membrane pro

216 The monoamine oxidase isoenzymes (MAOs) A and B play importa

217 es was synthesized and screened toward human monoamine oxidase isoforms (hMAO-A and hMAO-B).

218 hibitory properties tested for the two human monoamine oxidase isoforms (hMAOA and hMAOB).

219 The flavin-dependent monoamine oxidase LSD1 (lysine-specific demethylase 1, a

220 M1 family is homologous to the mitochondrial monoamine oxidases MAO-A/B and produces hydrogen peroxid

221 cids on the activity and solubility of human monoamine oxidase (MAO B), 10 sequential mutants were ma

222 its IC(50) against the functionally related monoamine oxidase (MAO) -A and MAO-B is >10 microM.

223 Monoamine oxidase (MAO) A and B catalyze the oxidative d

224 signed, synthesized, and evaluated for their monoamine oxidase (MAO) A and B inhibiting effect.

225 SY5Y markedly reduced the activities of both monoamine oxidase (MAO) A and B.

226 report for the first time that VPA activates monoamine oxidase (MAO) A catalytic activity, mRNA level

227 as recently suggested that partially reduced monoamine oxidase (MAO) A contains an equilibrium mixtur

228 studies have established that abrogation of monoamine oxidase (MAO) A expression leads to a neuroche

229 Monoamine oxidase (MAO) A is a key enzyme for the degrad

230 uran was a potent and selective inhibitor of monoamine oxidase (MAO) A.

231 ly demonstrated direct evidence of increased monoamine oxidase (MAO) activity in the brain of a simia

232 direct effects of CSC and A(2A) receptors on monoamine oxidase (MAO) activity, we found that CSC pote

233 ts structural analogues on the activities of monoamine oxidase (MAO) and ALDH-2, the key enzymes invo

234 tonin 5-HT1A receptor antagonist) as well as monoamine oxidase (MAO) and functional binding assays we

235 Previous studies have utilized monoamine oxidase (MAO) and L-3,4-dihydroxyphenylalanine

236 uate its potential to visualize and quantify monoamine oxidase (MAO) B activity in vivo.

237 Monoamine oxidase (MAO) B deaminates a number of biogeni

238 The human monoamine oxidase (MAO) B plays a major role in the degr

239 e amides also exhibited less potency against monoamine oxidase (MAO) enzymes and thus possess less po

240 Monoamine oxidase (MAO) expression was increased in cell

241 ough receptors R3 and R4 and the activity of monoamine oxidase (MAO) in the establishment of correct

242 late central monoamine levels partly through monoamine oxidase (MAO) inhibition.

243 Wistar rats and on rats pretreated with the monoamine oxidase (MAO) inhibitor clorgyline.

244 endogenous imidazoline ligand agmatine, the monoamine oxidase (MAO) inhibitor harmane, the alpha(2)-

245 ble dopamine-beta-monooxygenase (DbetaM) and monoamine oxidase (MAO) inhibitors.

246 Monoamine oxidase (MAO) is a key enzyme responsible for

247 Monoamine oxidase (MAO) is responsible for the oxidation

248 at cigarette smoke constituents that inhibit monoamine oxidase (MAO) may increase the reinforcing val

249 Monoamine oxidase (MAO) metabolizes cytosolic dopamine (

250 be an inactivator of the fungal flavoenzyme monoamine oxidase (MAO) N.

251 The flavoenzyme monoamine oxidase (MAO) regulates mammalian behavioral p

252 Monoamine oxidase (MAO) regulates neurotransmitter conce

253 wo-step homogeneous bioluminescent assay for monoamine oxidase (MAO) that is simple, sensitive, and a

254 ling in striatum: mitochondrial respiration, monoamine oxidase (MAO), and NADPH oxidase (Nox).

255 lamine), which is a monoamine metabolized by monoamine oxidase (MAO), exists widely in plants, animal

256 coding serotonin and dopamine receptors, and monoamine oxidase (MAO)-A in brains of sub-adult pigs we

257 Further, we have identified the monoamine oxidase (MAO)-aldehyde dehydrogenase (ALDH-2)

258 ine oxidases including polyamine oxidase and monoamine oxidase (MAO).

259 nd vasoactive dietary amines is oxidation by monoamine oxidase (MAO).

260 Tryptophan hydroxylase (TPH1) and monoamine oxidase (MAO-A) are the key enzymes for the sy

261 kidney diamine oxidase (pkDAO) or rat liver monoamine oxidase (MAO-B).

262 ein, a novel one-pot omega-transaminase (TA)/monoamine oxidase (MAO-N) cascade process for the synthe

263 Monoamine oxidases (MAO) A and B are approximately 60-kD

264 e inactivation of purified human recombinant monoamine oxidases (MAO) A and B by rasagiline [N-propar

265 Monoamine oxidases (MAO) A and B catalyze the oxidative

266 Monoamine oxidases (MAO) A and B deaminate a number of b

267 valuation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose

268 idative stress by limiting the expression of monoamine oxidases (MAO)--mitochondrial enzymes responsi

269 of the active site cavities in human and rat monoamine oxidases (MAOA and MAOB) have been studied in

270 Drug interaction between inhibitors of monoamine oxidase (MAOIs) and selective serotonin (5-hyd

271 arins were designed, prepared, and tested as monoamine oxidases (MAOs) and acetyl- and butyryl-cholin

272 The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent corr

273 endent amine oxidases, certain inhibitors of monoamine oxidases (MAOs), including the clinically used

274 carbonyl reductases (CREDs), hydrolases and monoamine oxidases (MAOs), providing a comprehensive ove

275 ds are capable of inducing the activities of monoamine oxidases (MAOs), which degrade monoamine neuro

276 d access to nicotine, and that inhibition of monoamine oxidase may contribute to the escalation of sm

277 The suggestion that polyamine oxidase and monoamine oxidase may have structural homology appears t

278 Previous studies have implicated the monoamine oxidase metabolite of DA, 3,4-dihydroxphenylac

279 ethyl transferase (COMT) and two isoforms of monoamine oxidase--modulated degree of belief learning a

280 n widely reported that renalase is the third monoamine oxidase (monoamine oxidase C) that oxidizes ci

281 inactivated with three known inactivators of monoamine oxidase, namely, phenylhydrazine, N-cyclopropy

282 g sites for [(18)F]AV-1451, such as neuronal monoamine oxidase or neuromelanin.

283 h extended (>30 ns) atomistic simulations of monoamine oxidase, revealing good agreement between the

284 ble and specific for LSD1 as compared to the monoamine oxidases shows minimal inhibition of CYPs and

285 3,4-dihydroxyphenylacetaldehyde (DOPAL) via monoamine oxidase significantly increases its toxicity.

286 ism of amine oxidation by this member of the monoamine oxidase structural family.

287 Polymorphisms in monoamine oxidase (T1460CA) were associated with increas

288 re, we demonstrate that AMX-2 is the primary monoamine oxidase that metabolizes 5-HT in C. elegans, a

289 to 3,4-dihydroxymandelic acid (DHMA) by the monoamine oxidase TynA and the aromatic aldehyde dehydro

290 d allele-specific expression of the X-linked monoamine oxidase type A (MAOA) gene and the expression

291 e carbidopa/levodopa, dopamine agonists, and monoamine oxidase type B (MAO-B) inhibitors.

292 this review, we focus on recent studies with monoamine oxidase type B inhibitors (selegiline and rasa

293 ptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine

294 gether with organic cation transporter 3 and monoamine oxidase type B, two key proteins for DA uptake

295 e (24-48 h), and after chronic inhibition of monoamine oxidase using phenelzine sulfate.

296 evelopment and application of a "toolbox" of monoamine oxidase variants from Aspergillus niger (MAO-N

297 Rat liver mitochondrial monoamine oxidase was also inactivated by 4, as expected

298 n DOPAL levels were blocked by inhibition of monoamine oxidase with clorgyline indicating that accumu

299 Moreover, inhibition of monoamine oxidase with daily administration of phenelzin

300 omolar concentration range for human and rat monoamine oxidases with slight preference for monoamine